Literature DB >> 8319212

Anticancer efficacy of Magainin2 and analogue peptides.

M A Baker1, W L Maloy, M Zasloff, L S Jacob.   

Abstract

Linear helical channel-forming peptides structurally similar to the Xenopus-derived antibiotic, Magainin2-amide, were synthesized. Because activity resides in the physicochemical properties of the peptides, an all-D-amino acid as well as an all-L-amino acid sequence were tested for anticancer activity. In vitro activity against carcinoma cells and in vivo efficacy against four murine ascites tumors were determined. The novel peptides proved to have enhanced potency in vitro and in vivo as compared to the parent compound. The 50% inhibitory concentrations against A549 cells for the all-D, the all-L, and Magainin2 were 6, 10, and 110 micrograms/ml, respectively. All three peptides had activity against P388 leukemia, S180 ascites, and a spontaneous ovarian tumor when injected i.p. Increase in life span of over 100% was produced for the analogues in the latter two models. The maximally effective concentrations for the analogues were 20 to 25 mg/kg while Magainin2 required 50-60 mg/kg for in vivo efficacy. The all-D-amino acid peptide, MSI-238, proved as effective as doxorubicin at a more advanced stage of the ovarian tumor and this activity may be attributed to its resistance to proteolytic degradation. Therefore, this class of amphiphilic alpha-helical cationic peptides has potential in the peritoneal treatment of ovarian cancer.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8319212

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  54 in total

Review 1.  Tumor cell membrane-targeting cationic antimicrobial peptides: novel insights into mechanisms of action and therapeutic prospects.

Authors:  Amy A Baxter; Fung T Lay; Ivan K H Poon; Marc Kvansakul; Mark D Hulett
Journal:  Cell Mol Life Sci       Date:  2017-08-02       Impact factor: 9.261

Review 2.  Nonmammalian vertebrate antibiotic peptides.

Authors:  P Síma; I Trebichavský; K Sigler
Journal:  Folia Microbiol (Praha)       Date:  2003       Impact factor: 2.099

Review 3.  The use of therapeutic peptides to target and to kill cancer cells.

Authors:  R J Boohaker; M W Lee; P Vishnubhotla; J M Perez; A R Khaled
Journal:  Curr Med Chem       Date:  2012       Impact factor: 4.530

Review 4.  Latarcins: versatile spider venom peptides.

Authors:  Peter V Dubovskii; Alexander A Vassilevski; Sergey A Kozlov; Alexey V Feofanov; Eugene V Grishin; Roman G Efremov
Journal:  Cell Mol Life Sci       Date:  2015-08-19       Impact factor: 9.261

5.  Application of 'inductive' QSAR descriptors for quantification of antibacterial activity of cationic polypeptides.

Authors:  Artem Cherkasov; Bojana Jankovic
Journal:  Molecules       Date:  2004-12-31       Impact factor: 4.411

Review 6.  Studies on anticancer activities of antimicrobial peptides.

Authors:  David W Hoskin; Ayyalusamy Ramamoorthy
Journal:  Biochim Biophys Acta       Date:  2007-11-22

7.  A pH-dependent charge reversal peptide for cancer targeting.

Authors:  Naoko Wakabayashi; Yoshiaki Yano; Kenichi Kawano; Katsumi Matsuzaki
Journal:  Eur Biophys J       Date:  2016-06-08       Impact factor: 1.733

8.  Online monitoring of metabolism and morphology of peptide-treated neuroblastoma cancer cells and keratinocytes.

Authors:  Sabine Drechsler; Jörg Andrä
Journal:  J Bioenerg Biomembr       Date:  2011-06-04       Impact factor: 2.945

9.  Comparison of the membrane association of two antimicrobial peptides, magainin 2 and indolicidin.

Authors:  H Zhao; J P Mattila; J M Holopainen; P K Kinnunen
Journal:  Biophys J       Date:  2001-11       Impact factor: 4.033

10.  Bovine lactoferricin inhibits basic fibroblast growth factor- and vascular endothelial growth factor165-induced angiogenesis by competing for heparin-like binding sites on endothelial cells.

Authors:  Jamie S Mader; Daniel Smyth; Jean Marshall; David W Hoskin
Journal:  Am J Pathol       Date:  2006-11       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.